BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Harvard Business School
Medtronic
Deloitte
UBS
Healthtrust
Accenture
Chubb
Covington

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,232,818

« Back to Dashboard

Which drugs does patent 7,232,818 protect, and when does it expire?

Patent 7,232,818 protects KYPROLIS and is included in one NDA.

This patent has sixty-nine patent family members in twenty-four countries.
Summary for Patent: 7,232,818
Title:Compounds for enzyme inhibition
Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Inventor(s): Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA), Borchardt; Ronald T. (Lawrence, KS), Bunin; Barry A. (San Mateo, CA), Crews; Craig M. (New Haven, CT), Musser; John H. (San Carlos, CA)
Assignee: Proteolix, Inc. (South San Francisco, CA)
Application Number:11/106,879
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,232,818

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-002 Jun 3, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-001 Jul 20, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,232,818

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,207,124 Compounds for enzyme inhibition ➤ Subscribe
7,417,042 Compounds for enzyme inhibition ➤ Subscribe
8,207,127 Compounds for enzyme inhibition ➤ Subscribe
7,491,704 Compounds for enzyme inhibition ➤ Subscribe
8,207,125 Compounds for enzyme inhibition ➤ Subscribe
8,198,270 Compounds for proteasome enzyme inhibition ➤ Subscribe
8,129,346 Compounds for enzyme inhibition ➤ Subscribe
8,324,174 Compounds for enzyme inhibition ➤ Subscribe
8,207,126 Compounds for enzyme inhibition ➤ Subscribe
8,207,297 Compounds for enzyme inhibition ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,232,818

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 494298 ➤ Subscribe
Austria 496062 ➤ Subscribe
Australia 2005238445 ➤ Subscribe
Australia 2005271232 ➤ Subscribe
Australia 2005295183 ➤ Subscribe
Australia 2012203602 ➤ Subscribe
Australia 2012211349 ➤ Subscribe
Brazil PI0509879 ➤ Subscribe
Brazil PI0514102 ➤ Subscribe
Canada 2562411 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
Chinese Patent Office
Medtronic
Cantor Fitzgerald
Cipla
Mallinckrodt
Chubb
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot